Pertuzumab and trastuzumab: the rationale way to synergy
Fuente:
Redalyc
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artículo científico |
| Lenguaje: | en |
| Publicado: |
Academia Brasileira de Ciências
2016
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1876460714393075712 |
|---|---|
| author | Sandrine Richard |
| author_facet | Sandrine Richard |
| contents | Pertuzumab and trastuzumab: the rationale way to synergy Sandrine Richard Frédéric Selle Jean-Pierre Lotz Ahmed Khalil Joseph Gligorov Daniele G. Soares Multidisciplinaria (Ciencias Naturales y Exactas) HER2 pertuzumab trastuzumab dimerization Breast cancer It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease, highlighting the need for new therapies. The continuous interest in novel targeted agents led to the development of pertuzumab, the first in a new class of agents, the HER dimerization inhibitors. Pertuzumab is a novel recombinant humanized antibody directed against extracellular domain II of HER2 protein that is required for the heterodimerization of HER2 with other HER receptors, leading to the activation of downstream signalling pathways. Pertuzumab combined with trastuzumab plus docetaxel was approved for the first-line treatment of patients with HER2-positive metastatic breast cancer and is currently used as a standard of care in this indication. In the neoadjuvant setting, the drug was granted FDA-accelerated approval in 2013. Pertuzumab is also being evaluated in the adjuvant setting. The potential of pertuzumab relies in the dual complete blockade of the HER2/3 axis when administered with trastuzumab. This paper synthesizes preclinical and clinical data on pertuzumab and highlights the mechanisms underlying the synergistic activity of the combination pertuzumab-trastuzumab which are essentially due to their complementary mode of action. 2016 artículo científico 0001-3765 https://www.redalyc.org/articulo.oa?id=32746362012 en http://www.redalyc.org/revista.oa?id=327 Anais da Academia Brasileira de Ciências application/pdf Academia Brasileira de Ciências Anais da Academia Brasileira de Ciências (Brasil) Num.1 Vol.88 |
| format | Artículo científico |
| id | redalyc_32746362012 |
| institution | Redalyc |
| language | en |
| publishDate | 2016 |
| publisher | Academia Brasileira de Ciências |
| spellingShingle | Pertuzumab and trastuzumab: the rationale way to synergy Sandrine Richard Multidisciplinaria (Ciencias Naturales y Exactas) HER2 pertuzumab trastuzumab dimerization Breast cancer Pertuzumab and trastuzumab: the rationale way to synergy Sandrine Richard Frédéric Selle Jean-Pierre Lotz Ahmed Khalil Joseph Gligorov Daniele G. Soares Multidisciplinaria (Ciencias Naturales y Exactas) HER2 pertuzumab trastuzumab dimerization Breast cancer It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease, highlighting the need for new therapies. The continuous interest in novel targeted agents led to the development of pertuzumab, the first in a new class of agents, the HER dimerization inhibitors. Pertuzumab is a novel recombinant humanized antibody directed against extracellular domain II of HER2 protein that is required for the heterodimerization of HER2 with other HER receptors, leading to the activation of downstream signalling pathways. Pertuzumab combined with trastuzumab plus docetaxel was approved for the first-line treatment of patients with HER2-positive metastatic breast cancer and is currently used as a standard of care in this indication. In the neoadjuvant setting, the drug was granted FDA-accelerated approval in 2013. Pertuzumab is also being evaluated in the adjuvant setting. The potential of pertuzumab relies in the dual complete blockade of the HER2/3 axis when administered with trastuzumab. This paper synthesizes preclinical and clinical data on pertuzumab and highlights the mechanisms underlying the synergistic activity of the combination pertuzumab-trastuzumab which are essentially due to their complementary mode of action. 2016 artículo científico 0001-3765 https://www.redalyc.org/articulo.oa?id=32746362012 en http://www.redalyc.org/revista.oa?id=327 Anais da Academia Brasileira de Ciências application/pdf Academia Brasileira de Ciências Anais da Academia Brasileira de Ciências (Brasil) Num.1 Vol.88 |
| title | Pertuzumab and trastuzumab: the rationale way to synergy |
| topic | Multidisciplinaria (Ciencias Naturales y Exactas) HER2 pertuzumab trastuzumab dimerization Breast cancer |
| url | https://www.redalyc.org/articulo.oa?id=32746362012 |